{"nctId":"NCT00032487","briefTitle":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)","startDateStruct":{"date":"2000-12-01","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":1791,"armGroups":[{"label":"Standard glycemic control","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin","Drug: Glimepiride","Drug: Rosiglitazone","Drug: Metformin"]},{"label":"Intensive glycemic control","type":"EXPERIMENTAL","interventionNames":["Drug: Insulin","Drug: Glimepiride","Drug: Rosiglitazone","Drug: Metformin"]}],"interventions":[{"name":"Insulin","otherNames":["Lente"]},{"name":"Glimepiride","otherNames":["Amaryl"]},{"name":"Rosiglitazone","otherNames":["Avandia"]},{"name":"Metformin","otherNames":["Glumetza"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with type 2 DM who are no longer responsive to maximum dose of one or more oral agents.\n\nExclusion Criteria:\n\n* Angina pectoris, Canadian Class I-II,\n* congestive heart failure, Class III-IV,\n* stroke, incapacitating or in last 6 months,\n* Myocardial infarction (MI) or invasive cardiovascular procedure within the past six months,\n* ongoing diabetic gangrene,\n* BMI \\> 40,\n* hemoglobinopathy that interferes with A1c monitoring,\n* serum creatinine \\> 1.6 mg/dL,\n* fasting C-peptide \\< 0.21 pmol/ml,\n* Alanine Amino Transaminase (ALT) \\> 3 times normal or serum bilirubin \\> 1.9 mg/dL,\n* malignancy or noncardiac life-threatening diseases making life expectancy \\< 5 years,\n* autonomic neuropathy,\n* symptomatic pancreatic insufficiency (endocrine or exocrine),\n* recurrent seizures within the past year,\n* hypopituitarism,\n* pregnancy, lactation, or planning a pregnancy,\n* active psychosis or substance abuse,\n* lack of access to a person who can assist or be called in an emergency,\n* underlying conditions that in the site PI's judgment may prevent adherence to protocol,\n* current participation in another clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary Major Macrovascular Events","description":"Myocardial infarction (MI), intervention for coronary artery or Peripheral Vascular Disease (PVD), severe inoperable Coronary Artery Disease (CAD), new or worsening Congestive Heart Failure (CHF), stroke, Cardiovascular (CV) death, or amputation for ischemic gangrene.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null},{"groupId":"OG001","value":"235","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary Endpoint","description":"New or worsening angina, new transient ischemic attack (TIA), new intermittent claudication or critical limb ischemia with Doppler evidence or total mortality.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"283","spread":null},{"groupId":"OG001","value":"312","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":144,"n":899},"commonTop":["Musculoskeletal","Infections","General Disorders","Nervous system","Gastrointestinal Disorders"]}}}